Similar articles

• Pharmacogenetic issues in thorough QT trials.

  Judson RS, Salisbury BA, Reed CR, Ackerman MJ. Judson RS, et al. Mol Diagn Ther. 2006;10(3):153-62. doi: 10.1007/BF03256454. Mol Diagn Ther. 2006. PMID: 16771601 Review.
• Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

  Shah RR. Shah RR. Drug Saf. 2004;27(3):145-72. doi: 10.2165/00002018-200427030-00001. Drug Saf. 2004. PMID: 14756578 Review.
• Pharmacogenetics of drugs withdrawn from the market.

  Zhang W, Roederer MW, Chen WQ, Fan L, Zhou HH. Zhang W, et al. Pharmacogenomics. 2012 Jan;13(2):223-31. doi: 10.2217/pgs.11.137. Pharmacogenomics. 2012. PMID: 22256871
• Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.

  Lauschke VM, Ingelman-Sundberg M. Lauschke VM, et al. Eur J Pharm Sci. 2019 Mar 15;130:65-77. doi: 10.1016/j.ejps.2019.01.024. Epub 2019 Jan 23. Eur J Pharm Sci. 2019. PMID: 30684656 Review.
• A pharmacogeneticist's look at drug effects and the drug development process: an overview.

  Kalow W. Kalow W. Expert Opin Pharmacother. 2005 Jul;6(8):1299-303. doi: 10.1517/14656566.6.8.1299. Expert Opin Pharmacother. 2005. PMID: 16013980 Review.